Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes

Florian Klomp; Christoph Wenzel; Marek Drozdzik; Stefan Oswald

doi:10.3390/pharmaceutics12121201

Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes

Pharmaceutics. 2020 Dec 11;12(12):1201. doi: 10.3390/pharmaceutics12121201.

Authors

Florian Klomp¹, Christoph Wenzel², Marek Drozdzik³, Stefan Oswald¹

Affiliations

¹ Institute of Pharmacology and Toxicology, Rostock University Medical Center, 18057 Rostock, Germany.
² Department of Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald, 17487 Greifswald, Germany.
³ Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland.

Abstract

Cytochrome P450 (CYP) 1A enzymes are considerably expressed in the human intestine and liver and involved in the biotransformation of about 10% of marketed drugs. Despite this doubtless clinical relevance, CYP1A1 and CYP1A2 are still somewhat underestimated in terms of unwanted side effects and drug-drug interactions of their respective substrates. In contrast to this, many frequently prescribed drugs that are subjected to extensive CYP1A-mediated metabolism show a narrow therapeutic index and serious adverse drug reactions. Consequently, those drugs are vulnerable to any kind of inhibition or induction in the expression and function of CYP1A. However, available in vitro data are not necessarily predictive for the occurrence of clinically relevant drug-drug interactions. Thus, this review aims to provide an up-to-date summary on the expression, regulation, function, and drug-drug interactions of CYP1A enzymes in humans.

Keywords: CYP1A1; CYP1A2; cytochrome P450; drug–drug interaction; expression; metabolism; regulation.

Publication types

Review